Clinical Trial Goal
To find out:
- The highest dose of ABBV-319 that’s safe to give
- If ABBV-319 is safe and works well to treat CLL, DLBCL and follicular lymphoma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have one of the following that has relapsed or is refractory:
- CLL
- DLBCL
- Follicular lymphoma
- Do not have lymphoma in your brain or spinal cord
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
ABBV-319 is a glucocorticoid that targets CD19 on certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
- ABBV-319 – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 2.5 years.
The Food and Drug Administration (FDA) has not yet approved ABBV-319.
Locations
Sponsors
lead: AbbVie
